Name: Taste receptor type 2 (TAS2R, T2R) - BioCentury Target Profiles - BCIQ
Creator: Biocentury

Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

Company Profiles
Target Profiles
Product Profiles

Explore BCIQ profiles by entering a target name.

REQUEST A FREE TRIAL

BioCentury | Feb 15, 2025

Finance

Orum, Aardvark IPOs trade in opposite directions: Public Equity Report

Largest KOSDAQ biotech offering since 2022 goes to protein degradation company; San Diego metabolic play gets lukewarm NASDAQ reception

BioCentury | Feb 7, 2025

Finance

Strong demand for Sionna latest good sign for IPOs: Public Equity Report

Vertex competitor posts a first-day gain after an upsized offering; plus financings for Gh Research and Tectonic

BioCentury | Jan 24, 2025

Finance

Ascentage lists on NASDAQ as Odyssey, Sionna, Aardvark plot IPOs

In BioCentury’s Finance Report, two more companies plan Hong Kong listings; Disc Medicine, Arctic raise cash

BioCentury | May 9, 2024

Finance

Venture report: Big rounds for Bluejay, Attovia and Zenas

Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT

BioCentury | Aug 10, 2023

Product Development

Obesity mechanisms in the clinic: which overlap, and which branch out

Like incretins, most clinical programs modulate glucose homeostasis and appetite, but a few work in new ways that could be more selective for fat loss

BioCentury | Jul 20, 2023

Data Byte